Agreement will support the integration of artificial intelligence technologies into microgravity-based pharmaceutical and life sciences research aboard Starlab’s commercial space station.
HOUSTON – July 8, 2026 – Starlab Space LLC, announced a reservation agreement with Space LiinTech Inc. (SLT), a South Korea-based space biopharma company developing AI-enabled microgravity research and manufacturing platforms. Through the agreement, Space LiinTech has secured future access to Starlab’s commercial microgravity laboratory, supporting the development of AI-enabled research and manufacturing capabilities in low Earth orbit.
Under the agreement, Space LiinTech plans to integrate its AI-driven technologies into future research conducted aboard Starlab. The collaboration will support pharmaceutical and life sciences applications that benefit from sustained microgravity conditions, including protein crystallization, 3D tissue engineering, and related biomanufacturing applications. By combining artificial intelligence with microgravity-enabled experimentation, the partnership aims to improve the quality of drug ingredients while enabling faster and more precise control of biological processes in orbit.
“The combination of microgravity and AI-enabled autonomous operations can expand how pharmaceutical research is designed, monitored, and translated into scalable services,” said Dr. Byungho Kim, Head of Space Pharmaceutical Business Division of Space LiinTech. “This partnership with Starlab supports our efforts to build a repeatable microgravity research platform and to connect Korea’s biopharma and space capabilities with the next generation of commercial low Earth orbit infrastructure.”
“Artificial intelligence has the potential to fundamentally improve how research is conducted in orbit,” said Marshall Smith, CEO of Starlab. “Space LiinTech’s approach combines advanced AI technologies with microgravity research capabilities in ways that could accelerate pharmaceutical development, improve experimental precision and expand international participation in the growing low Earth orbit economy.”
In South Korea, Space LiinTech recently secured government funding of up to US$12.8 million to advance the development of its space pharmaceutical platform.
The announcement builds on Starlab’s growing life sciences ecosystem, where microgravity creates conditions that reveal new insights into medicines, materials and biological systems. By enabling controlled experimentation in low Earth orbit, researchers can evaluate performance limits, refine formulations and advance product development pathways that may be difficult to replicate on Earth.
Starlab’s market-driven business model is designed to reduce cost, complexity and risk for researchers and commercial partners. Its single-launch, no-assembly-required architecture enables full certification and operational readiness within weeks from launch, minimizing delays and maximizing efficiency for payload customers. Through its joint venture partners, customers can conduct research aboard the International Space Station today, ensuring a seamless transition to Starlab as its next-generation capabilities come online.
###
About Starlab
Starlab Space is a U.S.-led, global joint venture among Voyager Technologies (NYSE: VOYG), Airbus, Mitsubishi Corporation, MDA Space, Palantir Technologies, and Space Applications Services, with strategic partners including Hilton, Journey, Northrop Grumman, and The Ohio State University. Starlab is developing a next-generation, AI-enabled commercial space station, aiming to ensure continued human presence in low-Earth orbit and a seamless transition of microgravity science and research alongside the retirement of the International Space Station. Starlab’s advanced, user-driven design and robust capabilities make it a premier platform for scientific discovery and technological advancement in space. For more information, visit starlab-space.com.
About Space LiinTech
Space LiinTech is a South Korea-based space biopharma company developing AI-enabled, microgravity platforms for pharmaceutical research and manufacturing. The company integrates artificial intelligence with space experimentation, autonomous operations, and ground-to-orbit validation to support protein crystallization, 3D tissue engineering, structural research, and advanced biomanufacturing applications in low Earth orbit. By leveraging AI-driven data analysis and automated decision-making, Space LiinTech is advancing a long-term vision to connect research, analysis, drug development, and commercial translation through a scalable and repeatable space biopharma platform. For more information, visit www.spaceliintech.com.
MEDIA CONTACT:
Starlab Space
Melissa Price, melissaprice@griffincg.com